Royalty Pharma RPRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.61B+4.9% | $2.49B+3.5% | $2.41B0.0% | $2.41B-10.9% | $2.7B-2.5% | ||
| -$2.6B-60.8% | -$1.61B-26.9% | -$1.27B+15.6% | -$1.51B+27.8% | -$2.09B+22.1% | ||
| $568.7M-53.7% | $1.23B+2.3% | $1.2B+4.3% | $1.15B+22.5% | $938.43M+309% | ||
| —— | —— | —— | —— | —— | ||
| -$501.33M-61.5% | -$310.33M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Royalty Pharma generate?
- Royalty Pharma (RPRX) generated $2.6B in operating cash flow over the trailing twelve months.
- Where does Royalty Pharma's cash flow data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
